06. 23. 2022

48% of US cancer clinical trials have no Hispanic or Latin American representation, and 42% do not include a single Black patient, Phesi analysis reveals

New analysis from Phesi  has found that 42% of US cancer trial cohorts do not include African American patients and 48% have no Hispanic American patients. Phesi analyzed 589,295 patients participating in 6,372 US-recruiting cancer clinical trials over the past 15 years…

Read more
06. 01. 2022

Use of digital twins will be essential in accelerating the use of CAR-T in cancer treatment and mitigating the side effects, says Phesi

Phesi has announced the creation of a digital twin for Cytokine Release Syndrome (CRS) patients following CAR-T therapy. CAR-T immunotherapies have become widely used in treatment of lymphomas, leukemia, and multiple myeloma; this trend is expected to increase. CRS is one of the most frequent and serious side effects of CAR-T therapy and has only one FDA-approved treatment, Tocilizumab. The difficulty of conducting clinical trials for such a serious and acute condition has held back new breakthroughs…

Read more
05. 06. 2022

Phesi global analysis of 2.5 million patients finds participants in breast cancer clinical trials are getting younger

New analysis from Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, has found that since 2014 the number of women younger than 60 years of age participating in breast cancer clinical trials has increased dramatically, with an overall increase in trial participants younger than 60 years of age from 30% to about 80% (Figure 1). The results emerge following a global analysis of 2,511,046 breast cancer patients from 4,674 investigator sites.

Read more
03. 21. 2022

New Phesi data highlights potential long-lasting impact from war in Ukraine on global clinical development

New global data analysis from Phesi shows that as of March 16, 2022, there were 65,593 recruiting investigator sites globally in this category. Of these, 2,911 (4.4%) sites were based in Ukraine and Russia (fig.1), with the majority of pharmaceutical trials currently in Phase III. A further 1,738 (2.6%) sites in neighboring Poland are also now at elevated risk as the war continues.

Read more